Aurobindo Pharma Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Voriconazole Tablets, 50 mg and 200 mg. This product is expected to be launched in the fourth quarter of fiscal year 2015-16. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) VFEND Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

Voriconazole Tablets is used in the treatment of fungal infections for patients 12 years of age and older. This is the 59th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 233 ANDA approvals (202 Final approvals including 10 from Aurolife Pharma LLC and 31 Tentative approvals) from USFDA.